Julián García-Feijoó, MD, PhD
Show Description +
Julián García-Feijoó, MD, PhD (Spain), reviews the European STAR-II clinical trial. Prof. García-Feijoó expands upon the similarities of the STAR-I trial and discusses the nuances of the study demographics. Patient qualified success rates at 6 months are also presented, along with the differences between medication free and on-medication patients, safety data, and adverse events. Six-month primary endpoint results from MINIject's European STAR-II trial showed powerful IOP and medication reduction. Read more in the Journal of Glaucoma, October 2020.
Posted: 11/11/2020
Julián García-Feijoó, MD, PhD
Julián García-Feijoó, MD, PhD (Spain), reviews the European STAR-II clinical trial. Prof. García-Feijoó expands upon the similarities of the STAR-I trial and discusses the nuances of the study demographics. Patient qualified success rates at 6 months are also presented, along with the differences between medication free and on-medication patients, safety data, and adverse events. Six-month primary endpoint results from MINIject's European STAR-II trial showed powerful IOP and medication reduction. Read more in the Journal of Glaucoma, October 2020.
Posted: 11/11/2020
About iSTAR Medical
Visit us online: istarmed.com
Follow iSTAR Medical